Registration - Level 2 Foyer

Continental Breakfast - Shanghai Ballroom & Pudong Ballroom Foyer

Rather than speaking in generalities, this session dives into specific China–global deals and expansion stories, from both biotechs and emerging biopharmas. Company leaders will walk through what happened: how the deal was structured, the roles each side played, what capabilities were needed (early discovery, global trials, commercial scale), and what they would do differently next time. The goal is to turn headline deals into practical playbooks for the rest of the ecosystem.

• For selected recent cross-border deals, what were the real turning points and non-negotiables on each side during negotiation and collaboration?
• How can companies bridge gaps in early discovery (new targets/MOAs) or later-stage global development and commercial capability?
• In which cases have Chinese biopharmas chosen to acquire overseas assets or platforms outright, and what did those deals look like compared with traditional in-licensing?
• What can smaller Chinese biotechs learn from more capability-rich Chinese biopharmas in structuring and sequencing their path to global markets?

Themes: Going Global / Collaboration & Partnerships / Regulatory Pathways / Commercialization / Dealmaking

In today’s market, the value of China-generated data is increasingly measured by one thing: its ability to support global deals and approvals. As development costs rise and capital becomes more selective, both Chinese and global companies are leveraging China’s CRO capabilities, patient access, and trial efficiency to accelerate Proof-of-Concept and strengthen ex-China partnering strategies. This session explores how companies are using China as a development engine while meeting Western regulatory expectations, and how strong China-generated data is shaping partnering decisions, deal terms, and global strategy.

• How are companies designing trial strategies that generate China data usable for US/EU filings?
• What capabilities (data quality, governance, biometrics, oversight) distinguish China trials that global partners trust?
• How does strong China PoC or Phase II data translate into deal value, structure, and negotiation leverage?
• What regulatory pitfalls must be avoided to ensure global acceptability under NMPA / FDA / EMA alignment?
• How can foreign companies run cost-effective trials in China while maintaining global governance?

Themes: Clinical Advantage / Regulatory Pathways / Strategy / Commercialisation

Based on a 100% anonymous survey of BD heads and senior dealmakers, this session reveals what people really think about geopolitical constraints, operational risk, and deal appetite, without attribution. A neutral panel analyses the data and focuses on pragmatic ways to keep cross-border dealmaking alive. This session will uncover:

• What operational risks are leaders most worried about in 2026?
• How are teams adjusting CMO/CRO/vendor choices to keep US/EU filings viable?
• How did respondents foresee license/M&A appetite shifting in the next 12 months?
• Which non-US players are gaining share, and at whose expense?

Themes: Geopolitics & Business Development / Investment Trends / Strategic Direction

As China’s biotech pipeline expands, global partners are becoming more selective in how they evaluate opportunities. This fireside explores what “deal-ready” really means in 2026, from differentiation and data quality to strategic fit, and why only a small proportion of assets ultimately translate into partnerships.

• What defines a “deal-ready” asset in today’s market?
• How are global partners benchmarking China-origin assets?
• Where do companies most often fall short in positioning or data?
• What early steps improve the likelihood of successful partnering?

Themes: Dealmaking / Strategy / Commercialization

As capital tightens and global commercialisation becomes more complex, many Chinese biotechs are rethinking the once-inevitable goal of becoming fully integrated biopharmas. This session explores whether building global commercial capabilities still makes sense, or whether a “partnership-led” model delivers better risk-adjusted returns in 2026. Leaders who have made these decisions candidly discuss what worked, what didn’t, and what they would do differently.

• Should Chinese companies still pursue full integration (R&D → clinical → manufacturing → ex-China commercial), or is a focused partnering model more realistic today?
• What capabilities, capital requirements, and timelines are actually needed to build ex-China commercial footprints?
• Where have integration efforts struggled, and what lessons can be drawn from recent pivots back to partnership-first strategies?
• How should management teams and boards evaluate build vs partner decisions at different stages of pipeline maturity?

Themes: Commercialization / Strategic Direction / Collaboration & Partnership / Dealmaking

China’s role in global development is no longer about access or speed; it's about consistently delivering trials that meet global standards. Behind every successful programme is a carefully structured ecosystem of CRO partners, high-performing sites, and operational oversight. This session explores how sponsors and biotechs are designing their clinical execution models in China to support global filings, partnerships, and investor confidence.

• What distinguishes CRO partners that consistently deliver global-ready trials in China?
• When does a local CRO model outperform global CRO structures, and where are the trade-offs?
• How are leading teams turning China’s patient access into predictable, high-quality recruitment?
• What site selection, governance, and oversight models drive consistency at scale?
• How does operational execution influence deal confidence, valuation, and partnering outcomes

Themes: Clinical Advantage / Execution Excellence / Global Readiness / Partnering Strategy